44 results about "Antiparasitic" patented technology

The invention discloses application of a propolis extract in preparation of a medicine for resisting Cryptosporidium parvum infection, and belongs to the technical field of biomedicine.The preparation method of the propolis extract comprises the steps that a propolis raw material is added into an extraction solvent according to the mass-to-volume ratio (g / mL) of 1: (5-20), extraction is conducted for 24-72 h at the temperature of 20-60 DEG C, then filtration is conducted, and the propolis extract is obtained. And concentrating the filtrate under reduced pressure, and drying to obtain the propolis extract. In a cryptosporidium parvum infected mouse model, the propolis extract shows a remarkable treatment effect; the propolis extract disclosed by the invention can play a role in resisting cryptosporidium parvum through a multi-target and multi-channel mechanism, has multiple biological effects of resisting parasites, inflammation, oxidation, immunoregulation, intestinal barrier protection and the like, and has good development potential and clinical application prospect.

The invention discloses an indole styryl oxadiazole bridging compound with toxoplasma gondii resisting activity, which is formed by bridging three pharmacophores of 3-indoleacetonitrile, oxadiazole and cinnamic acid. The invention relates to the technical field of antiparasite, and has the beneficial effects that the compound provides a new chemical entity for development of toxoplasma gondii resistant drugs, opens up a new direction for design of the antiparasite drugs, has a wide application prospect, and is suitable for industrial production. Particularly, the gene has an important transformation value in the aspects of immunodeficiency patient treatment and toxoplasma gondii prevention and control in the livestock breeding industry.

The present invention provides diazo compounds having anti-trypanosomal activity, with less or no side-effects. The diazo compounds are structural analogue of quinapyramine and possess characteristics necessary for the targeted pharmacologic action of anti trypanosomosis, with reduced cytotoxicity. The compounds were found to have less cytotoxicity, and identical or better anti- parasitemia effect as compared to conventional quinapyramine sulfate.

The present invention provides an anti-parasitic composition for use in the treatment or prevention of a parasitic infection in a mammal, the anti-parasitic composition comprising a macrolide, in particular a combination of ivermectin, abamectin and doramectin. The invention also provides a method of treating a parasitic infection in a mammal by administering to the mammal an effective amount of an anti-parasitic composition comprising ivermectin, abamectin, and doramectin, and a method of preparing the anti-parasitic composition.

A strap (3), two complementary fastening elements (4, 5) configured to close the collar (1) into a self-closing loop, a sheath (2) attached to the strap (3), said sheath (2) having an inner face with a micro-perforated body and an outer face made of waterproof material, the inner face having a pouch (11) with an opening (12) configured to allow the diffusion of an antiparasitic treatment molecule through said micro-perforated body. Figure for the abstract: Fig 1

A strap (3), two complementary closing elements (4, 5) configured to be able to close the collar (1) in a loop closed on itself, a sheath (2) linked to the strap (3), said sheath (2) comprising an inner face provided with a microperforated body and an outer face made of waterproof material, the inner face being provided with a pocket (11) having an opening (12) and configured to allow the diffusion of an antiparasitic treatment molecule through said microperforated body. Figure for the abstract: Fig 1

A topical formulation, comprising: an ointment base; and a mixture of active pharmaceutical ingredients (APIs) contained in the ointment base, the mixture of APIs consisting of: Metronidazole; Ivermectin; and Melaleuca alternifolia (tea tree) oil. The APIs are about 0.12%-6% w / w and the ointment base is about 94% to 99% w / w of the topical formulation. The formulation can further include enhancers for the APIs, such as, moisturizers and anti-oxidants. The formulation is configured as an anti-parasitic, anti-inflammatory and anti-microbial formulation.

Provided herein is a method of treating, preventing, or alleviating one or more symptoms of Chagas disease in a subject, comprising administering to the subject: (i) ascorbic acid, or a single enantiomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof; (ii) a quinone compound, or a single enantiomer, a mixture of enantiomers, or a mixture of diastereomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; and (iii) an antiparasitic agent.

The application belongs to the field of natural medicines, and particularly relates to cyclic peptide natural products-xylonic acid peptides and the use thereof in the preparation of anti-parasitic drugs. Specifically, 12 cyclic peptide natural products containing xylonic acid structural units are disclosed, which exhibit different degrees of anti-parasitic activity in biological activity tests and have wide application value.

The invention relates to a substituted benzamide derivative as well as a preparation method and application thereof, and belongs to the technical field of medicine synthesis. Specifically, the invention discloses a substituted benzamide derivative as shown in a general formula (I), a pharmaceutical composition containing the derivative and application of the derivative in preparation of anti-parasitic drugs. The structural general formula (I) of the substituted benzamide derivative is shown in the specification, wherein R1 is substituted amine. The substituted benzamide derivative disclosed by the invention has a remarkable effect on resisting parasites, vector insects and agricultural and forestry pests, and has a wide application prospect.

The present invention relates to a veterinary vaccine composition based on fatty-acid-binding proteins (FABP) from parasites. Specifically, the invention discloses a veterinary vaccine composition based on the Schistosoma mansoni protein (rSm14) or homologous proteins of Fasciola hepatica (FhFABPs) that provide a homogeneous, long-term immune response against parasitic worms. The invention is also intended to provide a method for treating and preventing infection caused by parasitic worms, in particular Fasciola hepatica, and also the use of these proteins in a vaccine composition against parasitic worms.

The present disclosure provides a method of inhibiting proliferation of a parasite or treating a disease caused by a parasite in a subject by administration of a mitochondria-targeted drug. Nonlimiting examples of the parasites include Brugia malayi and Dirofilaria immitis. Advantageously, movement of both male and female microfilaria can be inhibited by the mitochondria-targeted drug.

Disclosed herein are methods of eradicating ticks that attach to a human subject, thereby preventing potential transmission of vector-borne diseases including Lyme disease, via delivery of one, two, or more systemic doses of a lotilaner anti-parasitic therapeutic agent to the subject.

The invention provides an application of a modified quinazoline compound in preparation of an anti-parasitic composition. The compound provided by the invention has excellent anti-parasitic activity. The invention also provides a method for preparing the compound, the used raw materials are wide in source, and the preparation method is simple, convenient and practical.

The present invention discloses an indole styryl oxadiazole bridged compound having anti-Toxoplasma activity, comprising a compound formed by bridging three pharmacophores: 3-indoleacetonitrile, oxadiazole, and cinnamic acid. The present invention relates to the field of antiparasitic technology and has the beneficial effects of providing a new chemical entity for the development of anti-Toxoplasma drugs and opening up new directions for the design of antiparasitic drugs. The compound has broad application prospects, particularly in the treatment of immunocompromised patients and the prevention and control of Toxoplasma gondii in the livestock and aquaculture industry.

The invention relates to application of intestinal microbial metabolites in preparation of drugs for preventing and treating parasitic infection. The invention discloses an intestinal flora metabolite (desaminotyrosine, DAT), which can be used for enhancing a type 2 immune response and preventing and treating infection of parasites. The DAT is mainly an important phenolic acid product generated by metabolism of flavonoid compounds by clostridium, in a Nipostrongylus brasiliensis (Nb) infection model, the metabolite effectively relieves clinical symptoms of mice and promotes proliferation of Tuft cells during parasite infection, the Tuft cells can secrete IL-25 after being proliferated in mice normally drinking the DAT, and in addition, the Tuft cells can secrete IL-25 after being proliferated in the mice normally drinking the DAT. The Tuft cell-derived IL-25 further activates type 2 innate lymphoid cells (ILC2) to generate type 2 immune factors (IL-4 and IL-13), and proliferation of cluster cells accelerates removal of parasites and reduces intestinal injury. In addition, verification is carried out in a cluster cell knockout mouse, and deletion of cluster cells can accelerate proliferation of the Brazilian strongylus nematode and aggravate intestinal injury. The factors are crucial to anti-parasitic reaction of a human body, and the metabolite has a wide application prospect in preparations for preventing and treating parasitic infection.

The invention discloses an application of kochia saponin in preparation of a medicine for treating helminthosis, an in-vitro effectiveness experiment result of the kochia saponin on an echinococcosis multilocularis protoscolex shows that the killing effect of the kochia saponin on the protoscolex has time and concentration dependence, the death rates of 10 [mu] M, 20 [mu] M and 50 [mu] M of kochia saponin treated for 6 h are 8.05% + / -0.39%, 89.23% + / -1.48% and 100% respectively, and the death rates of 10 [mu] M, 20 [mu] M and 50 [mu] M of kochia saponin treated for 24 h are all 100%; meanwhile, results of in-vitro effectiveness experiments of kochia saponin on trichina at different development stages show that after the trichina is treated for 72 hours under the concentration of 50 mu M, 80 mu M and 100 mu M, the death rates of muscular larvae are 86.24% + / -1.15%, 90.17% + / -1.24% and 90.86% + / -2.10% respectively; after treatment for 24 hours, the death rates of the newborn larvae are respectively 12.71% + / -2.36%, 57.80% + / -2.23% and 79.60% + / -1.52%, all the newborn larvae die after 48 hours, and the killing effect is obvious. Besides, the applicant confirms that the mogroside can directly destroy the epidermis structure and cell integrity of the insect body for the first time through microscope observation, and the discovery provides visual morphological evidence for the anti-parasitic effect of the mogroside.

The invention discloses genetically engineered streptomyces as well as a construction method and application thereof. According to the present invention, an aveA3 fragment in a Streptomyces avermitilis gene cluster capable of generating an ivermectin B1b compound is replaced with a milA3 fragment in a Streptomyces hygroscopicus gene cluster so as to obtain the gene engineering Streptomyces, such as Streptomyces avermitilis HU501-M, and the gene engineering Streptomyces HU501-M can be used to produce the ivermectin B1b compound, such that the gene engineering Streptomyces HU501-M can be used to produce the ivermectin B1b compound, and the ivermectin B1b compound can be used to produce the ivermectin B1b compound, and the ivermectin B1b compound can be used to produce the ivermectin B1b compound, and can be used to produce the ivermectin B1b compound. The constructed genetically engineered streptomyces can be used for preparing milbemycin D, and the compound has efficient insecticidal, acaricidal and antiparasitic activity, is high in safety to human beings and animals, and is environment-friendly. The main fermentation product of the genetically engineered streptomyces is milbemycins D, and the genetically engineered streptomyces has a good industrial development prospect.

The present disclosure is directed to a method of detecting a helminth a antigen in a sample comprising (a) contacting a sample with human antibodies and fragments thereof, comprising clone-paired heavy and light chain CDR sequences, and (b) detecting a helminth antigen in said sample by binding of said human antibody or antibody fragment to a helminth antigen in said sample.

Anti-parasitic compounds and uses thereof. Compounds comprising a C-terminal peptide adjuvant conjugated to an N-terminal peptide antigen via a protease-cleavable linker, said peptide adjuvant comprising a peptide analog of C5a, wherein said peptide antigen comprises an antigenic epitope of a parasitic organism, such as T. gondii. Methods of therapeutic or prophylactic treatment of a parasitic infections.

A compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment of a patient infected with pathogenic organisms; wherein X and Y are each independently selected from C, N, O and S, provided at least one of X and Y is N, O or S; wherein R1 and R2 are each independently selected from an optionally substituted C1-C8 alkyl, C1-C8 alkenyl, aryl, heteroaryl or alkylaryl group; and wherein Z is selected from H, —CN, —NO2, —NR3R4, —NR5(CO)R6; C1-C4 alkyl, C1-C4 alkoxy, —(CO)WR12, hydroxy, amino, thiol, chloro, fluoro, CF3, CHF2 or CH2F groups. The compounds may be effective in treating patients / animals infected with parasites selected from Schistosoma, Haemonchus, Eimeria, Echinococcus, Dirofilaria, Fasciola or Plasmodium parasites. Additionally or alternatively, the compounds of formula (I) may be effective in treating patients infected with pathogenic bacteria selected from S. aureus, MRSA and Enterococcus faecalis.

The present invention relates to an isoxazoline derivative, its preparation method, and its application, belonging to the technical field of pharmaceutical synthesis. Specifically, the present invention discloses an isoxazoline derivative represented by general formula (I), a pharmaceutical composition containing the derivative, and its application in the preparation of an antiparasitic drug. The structural formula (I) of the isoxazoline derivative is: The isoxazoline derivative of the present invention is significantly effective in combating parasites, insect vectors, agricultural and forestry pests, and has broad application prospects.

The invention discloses an application of psoralen B in preparation of a medicine for treating helminthosis, an in-vitro effectiveness experiment result of psoralen B on an echinococcosis multilocularis protoscolex shows that the killing effect of maduramicin ammonium on the protoscolex has concentration dependence, the death rate of the protoscolex can reach 90.63% + / -0.96% after the maduramicin ammonium is treated for 6 h at the concentration of 50 mu M, and the death rate of the protoscolex can reach 90.63% + / -0.96% at the concentration of 100 mu M, and the death rate of the maduramicin ammonium can reach 90.63% + / -0.96% at the concentration of 100 mu M. The death rate of the original head section can directly reach 100%; meanwhile, in-vitro effectiveness experiment results of psoralen B on trichina at different development stages show that after the trichina is treated for 72 hours under the concentration of 50 mu M, 80 mu M and 100 mu M, the death rates of muscular larvae reach 89.44% + / -0.81%, 96.29% + / -1.30% and 96.68% + / -1.06% respectively; after 48 hours of treatment, the death rate of the adults is 100%, and the killing effect is remarkable. More importantly, the applicant verifies that IBC can directly destroy the epidermal structure and cell integrity of the insect body for the first time through observation by an optical microscope and an electron microscope, and the discovery provides intuitive morphological evidence for the anti-parasitic effect of IBC.

The invention belongs to the field of synthetic biology and microbial pharmacy, and particularly relates to recombinant streptomyces, a construction method of the recombinant streptomyces and application of the recombinant streptomyces in preparation of savermectin B. According to the present invention, after the aveA1 gene segment in the abamectin biosynthesis gene cluster in the streptomyces avermectin is replaced with the nemA1 gene segment in the nemadectin biosynthesis gene cluster in the streptomyces blue griseolus, the recombinant streptomyces capable of producing the 16-membered macrolide compound-Sesvermectin B (Senvermectin B), such as the recombinant streptomyces avermectin HU520-M provided by the invention, is obtained; experiments show that the savermectin B has efficient insecticidal, acaricidal and anti-parasitic activity, and shows good industrial development potential.